Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Alzheimer’s Disease: A Real‑World Retrospective Cohort Study with Treatment Effect Heterogeneity Analysis
Mortality risks vary substantially across SGAs in patients with AD with single-medication usage. Aripiprazole and quetiapine were associated with lower mortality compared with olanzapine and risperidone. Treatment effect heterogeneity suggests the need for individualized prescribing based on patient characteristics such as comorbid T2DM.
Authors
- Julia Kofler (ORCID: https://orcid.org/0000-0003-4298-7328)
- Josh M. Krivinko (ORCID: https://orcid.org/0000-0003-3748-6510)
- Zeshui Yu (ORCID: https://orcid.org/0009-0002-4535-8770)
- Hui Wang (ORCID: https://orcid.org/0000-0002-1152-5860)
- Chen Jiang (ORCID: https://orcid.org/0000-0001-8336-6814)
- Lirong Wang (ORCID: https://orcid.org/0000-0002-9092-6282)
- Lang Zeng (ORCID: https://orcid.org/0000-0002-9004-5063)
- Zheng Zeng
- Robert A. Sweet
- Ying Ding
Institutions
- University of Pittsburgh (US)
- Department of Health (TW)
- University of Pittsburgh Medical Center (US)
- Lumentum (United States) (US)
Publication Details
- Journal
- CNS Drugs
- Published
- 2026-03-28
- DOI
- https://doi.org/10.1007/s40263-026-01286-9
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00